Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics

Neuroscience Letters

Volumn 479, Issue 3, 2010, Pages 317-320

  Padurariu, Manuela ^a   Ciobica, Alin ^b,c   Dobrin, Irina ^a   Stefanescu, Cristinel ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b ALEXANDRU IOAN CUZA UNIVERSITY OF IASI   (Romania)

^c ACADEMY OF ROMANIAN SCIENTISTS   (Romania)

Author keywords

Antipsychotics; Oxidative stress; Schizophrenia

Indexed keywords

ANTIOXIDANT; ATYPICAL ANTIPSYCHOTIC AGENT; GLUTATHIONE PEROXIDASE; HALOPERIDOL; MALONALDEHYDE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SUPEROXIDE DISMUTASE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; ENZYME ACTIVITY; FEMALE; HUMAN; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSITIVITY ANALYSIS; SMOKING; DRUG EFFECTS; METABOLISM; MIDDLE AGED;

ADULT; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; GLUTATHIONE PEROXIDASE; HALOPERIDOL; HUMANS; LIPID PEROXIDATION; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; RISPERIDONE; SCHIZOPHRENIA; SUPEROXIDE DISMUTASE;

EID: 77954145692     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.05.088     Document Type: Article

References (45)

1. Akyol O., Herken H., Uz E., Fadillioglu E., Unal S., Sogut S. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. the possible role of oxidant/antioxidant imbalance. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:995-1005.
2. Arvindakshan M., Sitasawad S., Debsikdar V., Ghate M., Evans D., Horrobin D.F. Essential polyunsaturated fatty acid and lipid peroxide levels in nevermedicated and medicated schizophrenia patients. Biol. Psychiatry 2003, 53:56-64.
3. Azevedo M.H., Soares M.J., Coelho I., Dourado A., Valente J., Macedo A. Using consensus OPCRIT diagnoses. an efficient procedure for best estimate lifetime diagnoses. Br. J. Psychiatry 1999, 175:154-157.
4. Dadheech G., Mishra S., Gautam S., Sharma P. Evaluation of antioxidant deficit in schizophrenia. Indian J. Psychiatry 2008, 50:16-20.
5. Dakhale G., Khanzode S., Khanzode S., Saoji A., Khobragade L., Turankar A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 2004, 49:205-209.
6. Dietrich-Muszalska A., Olas B., Rabe-Jablonska J. Oxidative stress in blood platelets from schizophrenic patients. Platelets 2005, 16:386-391.
7. Gama C.S., Salvador M., Andreazza A.C., Kapczinski F., Silva Belmonte-de-Abreu P. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:512-515.
8. Gama C.S., Salvador M., Andreazza A.C., Lobato M.I., Berk M., Kapczinski F. Elevated serum thiobarbituric acid reactive substances in clinically symptomatic schizophrenic males. Neurosci. Lett. 2008, 433:270-273.
9. Grignon S., Chianetta J.M. Assessment of malondialdehyde levels in schizophrenia: a meta-analysis and some methodological considerations. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:365-369.
10. Herken H., Uz E., Ozyurt H., Söĝüt S., Virit O., Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol. Psychiatry 2001, 6:66-73.
11. Hritcu L., Ciobica A., Gorgan L. Nicotine-induced memory impairment by increasing brain oxidative stress. Cent. Eur. J. Biol. 2009, 4:335-342.
12. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-medicated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res. 2002, 58:1-10.
13. Kropp S., Kern V., Lange K., Degner D., Hajak G., Kornhuber J., Rüther E., Emrich H.M., Schneider U., Bleich S. Oxidative stress during treatment with first- and second-generation antipsychotics. J. Neuropsychiatry. Clin. Neurosci. 2005, 17:227-231.
14. Kuloglu M., Ustundag B., Atmaca M., Canatan H., Tezcan A.E., Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem. Funct. 2002, 20:171-175.
15. Kunz M., Gama C.S., Andreazza A.C., Salvador M., Ceresér K.M., Gomes F.A., Belmonte-de-Abreu P.S., Berk M., Kapczinski F. Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1677-1681.
16. Mahadik S.P., Evans D.R. Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications. Psychiatr. Clin. North Am. 2003, 26:85-102.
17. Mahadik S.P., Evans D., Lal H. Oxidative stress and role of antioxidant and ω-3 essential fatty acid supplementation in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2001, 25:463-493.
18. Martins M.R., Petronilho F.C., Gomes K.M., Dal-Pizzol F., Streck E.L., Quevedo J. Antipsychotic-induced oxidative stress in rat brain. Neurotoxicol. Res. 2008, 13:63-69.
19. Melamed Y., Sirota P., Dicker D.R., Fishman P. Superoxide anion production by neutrophils derived from peripheral blood of schizophrenic patients. J. Psychiatr. Res. 1998, 77:29-34.
20. Miljevic C., Nikolic M., Nikolic-Kokic A., Jones D.R., Niketic V., Lecic-Tosevski D., Spasic M.B. Lipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34:303-307.
21. Padurariu M, Ciobica A., Hritcu L., Stoica B., Bild W., Stefanescu C. Changes of some oxidative stress markers in the serum of patients with mild cognitive impairment and Alzheimer's disease. Neurosci. Lett. 2010, 469:6-10.
22. Parikh V., Khan M.M., Mahadik S.P. Differential effects of antipsychotics on expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 2003, 37:43-51.
23. Pavlović D., Tamburić V., Stojanović I. Oxidative stress as marker of positive symptoms in schizophrenia. Fact. Uni. Med. Biol. 2002, 9:157-161.
24. Petronijevic N.D., Micic D.V., Duricic B., Marinkovic D., Paunovic V.R. Substrate kinetics of erythrocyte membrane Na,K-ATPase and lipid peroxides in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:431-440.
25. Pillai A., Parikh V., Terry A.V., Mahadik S.P. Long-term antipsychotic treatments and crossover studies in rats: differential effects of typical and atypical agents on the expression of antioxidant enzymes and membrane lipid peroxidation in rat brain. J. Psychiatr. Res. 2007, 41:372-386.
26. Polydoro M., Schroder N., Lima M.N., Caldana F., Laranja D.C., Bromberg E., Roesler R., Quevedo J., Moreira J.C., Dal-Pizzol F. Haloperidol and clozapine-induced oxidative stress in the rat brain. Pharmacol. Biochem. Behav. 2004, 78:751-756.
27. Raffa M., Mechri A., Othman L.B., Fendri C., Gaha L., Kerkeni A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:1178-1183.
28. Reddy R.D., Keshavan M.S., Yao J.K. Reduced red blood cell membrane essential polyunsaturated fatty acids in first episode schizophrenia at neuroleptic-naive baseline. Schizophr. Bull. 2004, 30:901-911.
29. Reinke A., Martins M.R., Lima M.S., Moreira J.C., Dal-Pizzol F., Quevedo J. Haloperidol and clozapine, but not olanzapine, induces oxidative stress in rat brain. Neurosci. Lett. 2004, 372:157-160.
30. Rukmini M.S, D'Souza B., D'Souza V. Superoxide dismutase and catalase activities and their correlation with malondialdehyde in schizophrenic patients. Indian J. Clin. Biochem. 2004, 19:114-118.
31. Sarandol A., Kirli S., Akkaya C., Altin A., Demirci M., Sarandol E. Oxidative-antioxidative systems and their relation with serum S 100 B levels in patients with schizophrenia: effects of short term antipsychotic treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 2007, 31:1164-1169.
32. Singh O.P., Chakraborty I., Dasgupta A., Datta S. A comparative study of oxidative stress and interrelationship of important antioxidants in haloperidol and olanzapine treated patients suffering from schizophrenia. Indian J. Psychiatry 2008, 50:171-176.
33. Srivastava N., Barthwal M., Dalal P., Agarwal A.K., Nag D., Srimal R.C., Seth P.K., Dikshit M. Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology 2001, 158:140-145.
34. Sultana R., Piroddi M., Galli F., Butterfield D.A. Protein levels and activity of some antioxidant enzymes in hippocampus of subjects with amnestic mild cognitive impairment. Neurochem. Res. 2008, 33:2540-2546.
35. Wang H., Xu H., Dyck L.E., Li X.M. Olanzapine and quetiapine protect PC12 cells from beta-amyloid peptide(25-35)-induced oxidative stress and the ensuing apoptosis. J. Neurosci. Res. 2005, 81:572-580.
36. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64:663-667.
37. Wood S.J., Yücel M., Pantelis C., Berk M. Neurobiology of schizophrenia spectrum disorders: the role of oxidative stress. Ann. Acad. Med. Singapore 2009, 38:396-406.
38. Xu H., Wang H., Zhuang L., Yan B., Yu Y., Wei Z., Zhang Y., Dyck L.E., Richardson S.J., He J., Li X., Kong J., Li X.M. Demonstration of an anti-oxidative stress mechanism of quetiapine: implications for the treatment of Alzheimer's disease. FEBS J. 2008, 275:3718-3728.
39. Yao J.K., Reddy R., McElhinny L.G., van Kammen D.P. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J. Psychiatr. Res. 1998, 32:385-391.
40. Yao J.K., Reddy R., van Kammen D.P. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. J. Psychiatr. Res. 2000, 97:137-151.
41. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., Zhou D.F. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr. Res. 2006, 81:291-300.
42. Zhang X.Y., Zhou D.F., Cao L.Y., Chen D.C., Zhu F.Y., Wu G.Y. Blood superoxide dismutase level in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr. Res. 2003, 62:245-250.
43. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y. Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. J. Psychiatr. Res. 2003, 117:85-88.
44. Zhang X.Y., Zhou D.F., Su J.M., Zhang P.Y. The effect of extract of Ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia. J. Clin. Psychopharmacol. 2001, 21:85-88.
45. Zhang X.Y., Zhou D.F., Zhang P.Y., Wu G.Y., Su J.M., Cao L.Y. A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J. Clin. Psychiatry 2001, 62:878-883.